Jasper Therapeutics, Inc. (NASDAQ:JSPRW) Sees Significant Drop in Short Interest

Jasper Therapeutics, Inc. (NASDAQ:JSPRW) was the target of a large drop in short interest in February. As of February 13th, there was short interest totaling 4,289 shares, a drop of 19.4% from the January 29th total of 5,320 shares. Based on an average daily trading volume, of 22,585 shares, the short-interest ratio is presently 0.2 days. Based on an average daily trading volume, of 22,585 shares, the short-interest ratio is presently 0.2 days.

Jasper Therapeutics Trading Up 5.8%

Jasper Therapeutics stock traded up $0.00 during mid-day trading on Wednesday, reaching $0.02. 8,485 shares of the company traded hands, compared to its average volume of 26,244. Jasper Therapeutics has a fifty-two week low of $0.02 and a fifty-two week high of $0.18. The firm’s fifty day moving average is $0.04 and its two-hundred day moving average is $0.08.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on developing a new generation of cellular therapeutics for severe diseases. The company’s mission centers on harnessing targeted biological agents and engineered cell platforms to improve outcomes in hematopoietic stem cell transplantation, oncology and gene therapies. By advancing novel approaches to conditioning regimens and cell engineering, Jasper aims to address limitations of existing treatments, including toxicity, graft failure and restricted applicability.

The company’s lead candidate, JSP191, is a humanized monoclonal antibody targeting the CD117 receptor on hematopoietic stem cells.